Trial Profile
An Open-Label, Phase Ib, Dose-Escalation Study of the Safety and Pharmacology of the Anti-CD40 Monoclonal Antibody SGN-40 Administered in Combination With Bortezomib (Velcade, PS-341) in Patients With Relapsed or Refractory Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Dec 2022
Price :
$35
*
At a glance
- Drugs Dacetuzumab (Primary) ; Bortezomib
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Genentech
- 14 Nov 2011 Actual end date Apr 2010 added as reported by ClinicalTrials.gov.
- 31 Mar 2010 Actual patient number (18) added as reported by ClinicalTrials.gov.
- 31 Mar 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.